Blinding in randomized control trials: the enigma unraveled.

  • Vartika Saxena
  • Manisha Naithani
  • Anissa Atif Mirza

Abstract

The search for new treatments and testing of new ideas begins in the laboratory and then established in clinical research settings. Studies addressing the same therapeutic problem may produce conflicting results hence Randomised Clinical Trial is regarded as the most valid method for assessing the benefits and harms of healthcare interventions. The next challenge face by the medical community is the validity of such trials as theses tend to deviate from the truth because of various biases. For the avoidance of the same it has been suggested that the validity or quality of primary trials should be assessed under blind conditions. Thus blinding, is a crucial method for reducing bias in randomized clinical trials. Blinding can be defined as withholding information about the assigned interventions from people involved in the trial who may potentially be prejudiced by this knowledge. In this article we make an effort to define blinding, explain its chronology, hierarchy and discuss methods of blinding, its assessment, its possibility, un-blinding and finally the latest guidelines.

Downloads

Download data is not yet available.
Published
2016-03-31
How to Cite
1.
Saxena V, Naithani M, Mirza A. Blinding in randomized control trials: the enigma unraveled. Indian J Community Health [Internet]. 31Mar.2016 [cited 19Apr.2019];28(1):4-. Available from: http://www.iapsmupuk.org/journal/index.php/IJCH/article/view/639
Section
Review Article

Most read articles by the same author(s)